Lipid-Based Nanoparticles: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Nora Tang and Version 1 by Thai Thanh Hoang Thi.

COVID-19 vaccines have been developed with unprecedented speed which would not have been possible without decades of fundamental research on delivery nanotechnology. Lipid-based nanoparticles have played a pivotal role in the successes of COVID-19 vaccines and many other nanomedicines, such as Doxil® and Onpattro®, and have therefore been considered as the frontrunner in nanoscale drug delivery systems. In this review, we aim to highlight the progress in the development of these lipid nanoparticles for various applications, ranging from cancer nanomedicines to COVID-19 vaccines. The lipid-based nanoparticles discussed in this review are liposomes, niosomes, transfersomes, solid lipid nanoparticles, and nanostructured lipid carriers. We particularly focus on the innovations that have obtained regulatory approval or that are in clinical trials. We also discuss the physicochemical properties required for specific applications, highlight the differences in requirements for the delivery of different cargos, and introduce current challenges that need further development. This review serves as a useful guideline for designing new lipid nanoparticles for both preventative and therapeutic vaccines including immunotherapies.

  • lipid nanoparticles
  • liposomes
  • vaccines
  • immunotherapy
  • COVID-19
Please wait, diff process is still running!

References

  1. Ventola, C.L. Progress in nanomedicine: Approved and investigational nanodrugs. PT Peer-Rev. J. Formul. Manag. 2017, 42, 742–755.
  2. Bobo, D.; Robinson, K.J.; Islam, J.; Thurecht, K.J.; Corrie, S.R. Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharm. Res. 2016, 33, 2373.
  3. Anselmo, A.C.; Mitragotri, S. Nanoparticles in the clinic: An update. Bioeng. Transl. Med. 2019, 4, e10143.
  4. Germain, M.; Caputo, F.; Metcalfe, S.; Tosi, G.; Spring, K.; Åslund, A.K.O.; Pottier, A.; Schiffelers, R.; Ceccaldi, A.; Schmid, R. Delivering the power of nanomedicine to patients today. J. Control. Release 2020, 326, 164–171.
  5. Sabnis, S.; Kumarasinghe, E.S.; Salerno, T.; Mihai, C.; Ketova, T.; Senn, J.J.; Lynn, A.; Bulychev, A.; McFadyen, I.; Chan, J.; et al. A novel amino lipid series for mRNA delivery: Improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 2018, 26, 1509–1519.
  6. Shah, S.; Dhawan, V.; Holm, R.; Nagarsenker, M.S.; Perrie, Y. Liposomes: Advancements and innovation in the manufacturing process. Adv. Drug Deliv. Rev. 2020, 154–155, 102–122.
  7. Lu, W.; Yao, J.; Zhu, X.; Qi, Y. Nanomedicines: Redefining traditional medicine. Biomed. Pharmacother. 2021, 134, 111103.
  8. Soininen, S.K.; Repo, J.K.; Karttunen, V.; Auriola, S.; Vahakangas, K.H.; Ruponen, M. Human placental cell and tissue uptake of doxorubicin and its liposomal formulations. Toxicol. Lett. 2015, 239, 108–114.
  9. Barenholz, Y. Doxil(R)-the first FDA-approved nano-drug: Lessons learned. J. Control. Release 2012, 160, 117–134.
  10. Khvorova, A.; Watts, J.K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 2017, 35, 238–248.
  11. Reichmuth, A.M.; Oberli, M.A.; Jaklenec, A.; Langer, R.; Blankschtein, D. mRNA vaccine delivery using lipid nanoparticles. Ther. Deliv. 2016, 7, 319–334.
  12. Samaridou, E.; Heyes, J.; Lutwyche, P. Lipid nanoparticles for nucleic acid delivery: Current perspectives. Adv. Drug Deliv. Rev. 2020, 154–155, 37–63.
  13. Nakamura, T.; Harashima, H. Dawn of lipid nanoparticles in lymph node targeting: Potential in cancer immunotherapy. Adv. Drug Deliv. Rev. 2020, 167, 78–88.
  14. Ickenstein, L.M.; Garidel, P. Lipid-based nanoparticle formulations for small molecules and RNA drugs. Expert Opin. Drug Deliv. 2019, 16, 1205–1226.
  15. Kulkarni, J.A.; Witzigmann, D.; Leung, J.; Tam, Y.Y.C.; Cullis, P.R. On the role of helper lipids in lipid nanoparticle formulations of siRNA. Nanoscale 2019, 11, 21733–21739.
  16. Akinc, A.; Maier, M.A.; Manoharan, M.; Fitzgerald, K.; Jayaraman, M.; Barros, S.; Ansell, S.; Du, X.; Hope, M.J.; Madden, T.D.; et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 2019, 14, 1084–1087.
  17. Böttger, R.; Pauli, G.; Chao, P.-H.; Al Fayez, N.; Hohenwarter, L.; Li, S.-D. Lipid-based nanoparticle technologies for liver targeting. Adv. Drug Deliv. Rev. 2020, 154–155, 79–101.
  18. Semple, S.C.; Akinc, A.; Chen, J.; Sandhu, A.P.; Mui, B.L.; Cho, C.K.; Sah, D.W.Y.; Stebbing, D.; Crosley, E.J.; Yaworski, E.; et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 2010, 28, 172–176.
  19. Hassett, K.J.; Benenato, K.E.; Jacquinet, E.; Lee, A.; Woods, A.; Yuzhakov, O.; Himansu, S.; Deterling, J.; Geilich, B.M.; Ketova, T.; et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA Vaccines. Mol. Ther. Nucleic Acids 2019, 15, 1–11.
  20. Ramezanpour, M.; Schmidt, M.L.; Bodnariuc, I.; Kulkarni, J.A.; Leung, S.S.W.; Cullis, P.R.; Thewalt, J.L.; Tieleman, D.P. Ionizable amino lipid interactions with POPC: Implications for lipid nanoparticle function. Nanoscale 2019, 11, 14141–14146.
  21. Jayaraman, M.; Ansell, S.M.; Mui, B.L.; Tam, Y.K.; Chen, J.; Du, X.; Butler, D.; Eltepu, L.; Matsuda, S.; Narayanannair, J.K.; et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. 2012, 51, 8529–8533.
  22. Kulkarni, J.A.; Darjuan, M.M.; Mercer, J.E.; Chen, S.; van der Meel, R.; Thewalt, J.L.; Tam, Y.Y.C.; Cullis, P.R. On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA. ACS Nano 2018, 12, 4787–4795.
  23. Ely, A.; Singh, P.; Smith, T.S.; Arbuthnot, P. In vitro transcribed mRNA for expression of designer nucleases: Advantages as a novel therapeutic for the management of chronic HBV infection. Adv. Drug Deliv. Rev. 2020.
  24. Mashel, T.V.; Tarakanchikova, Y.V.; Muslimov, A.R.; Zyuzin, M.V.; Timin, A.S.; Lepik, K.V.; Fehse, B. Overcoming the delivery problem for therapeutic genome editing: Current status and perspective of non-viral methods. Biomaterials 2020, 258, 120282.
  25. Tapeinos, C.; Battaglini, M.; Ciofani, G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J. Control. Release 2017, 264, 306–332.
  26. Yonezawa, S.; Koide, H.; Asai, T. Recent advances in siRNA delivery mediated by lipid-based nanoparticles. Adv. Drug Deliv. Rev. 2020, 154–155, 64–78.
  27. Chacko, I.A.; Ghate, V.M.; Dsouza, L.; Lewis, S.A. Lipid vesicles: A versatile drug delivery platform for dermal and transdermal applications. Colloids Surf. B Biointerfaces 2020, 195, 111262.
  28. Opatha, S.A.T.; Titapiwatanakun, V.; Chutoprapat, R. Transfersomes: A promising nanoencapsulation technique for transdermal drug delivery. Pharmaceutics 2020, 12, 855.
  29. Duan, Y.; Dhar, A.; Patel, C.; Khimani, M.; Neogi, S.; Sharma, P.; Siva Kumar, N.; Vekariya, R.L. A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems. RSC Adv. 2020, 10, 26777–26791.
  30. Bhardwaj, P.; Tripathi, P.; Gupta, R.; Pandey, S. Niosomes: A review on niosomal research in the last decade. J. Drug Deliv. Sci. Technol. 2020, 56, 101581.
  31. Jain, S.; Tripathi, S.; Tripathi, P.K. Invasomes: Potential vesicular systems for transdermal delivery of drug molecules. J. Drug Deliv. Sci. Technol. 2020, 102166.
  32. Nasirizadeh, S.; Malaekeh-Nikouei, B. Solid lipid nanoparticles and nanostructured lipid carriers in oral cancer drug delivery. J. Drug Deliv. Sci. Technol. 2020, 55, 101458.
  33. Xu, Y.; Michalowski, C.B.; Beloqui, A. Advances in lipid carriers for drug delivery to the gastrointestinal tract. Curr. Opin. Colloid Interface Sci. 2020, 101414.
  34. Salah, E.; Abouelfetouh, M.M.; Pan, Y.; Chen, D.; Xie, S. Solid lipid nanoparticles for enhanced oral absorption: A review. Colloids Surf. B Biointerfaces 2020, 196, 111305.
  35. Freitas, C.; Müller, R.H. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm. 1999, 47, 125–132.
  36. Laffleur, F.; Keckeis, V. Advances in drug delivery systems: Work in progress still needed? Int. J. Pharm. 2020, 590, 119912.
  37. Zhang, Y.; Zhang, P.; Zhu, T. Ovarian carcinoma biological nanotherapy: Comparison of the advantages and drawbacks of lipid, polymeric, and hybrid nanoparticles for cisplatin delivery. Biomed. Pharm. 2019, 109, 475–483.
  38. Basha, S.K.; Dhandayuthabani, R.; Muzammil, M.S.; Kumari, V.S. Solid lipid nanoparticles for oral drug delivery. Mater. Today Proc. 2020, 36, 313–324.
  39. Veiga, N.; Diesendruck, Y.; Peer, D. Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes. Adv. Drug Deliv. Rev. 2020, 159, 364–376.
  40. Nakamura, T.; Kawai, M.; Sato, Y.; Maeki, M.; Tokeshi, M.; Harashima, H. The effect of size and charge of lipid nanoparticles prepared by microfluidic mixing on their lymph node transitivity and distribution. Mol. Pharm. 2020, 17, 944–953.
  41. Oussoren, C.; Zuidema, J.; Crommelin, D.J.A.; Storm, G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: II. Influence of liposomal size, lipid composition and lipid dose. Biochim. Biophys. Acta Biomembr. 1997, 1328, 261–272.
  42. Wisse, E.; de Zanger, R.B.; Charels, K.; van der Smissen, P.; McCuskey, R.S. The liver sieve: Considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of disse. Hepatology 1985, 5, 683–692.
  43. Younis, M.A.; Khalil, I.A.; Elewa, Y.H.A.; Kon, Y.; Harashima, H. Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo. J. Control Release 2021, 331, 335–349.
  44. Widmer, J.; Thauvin, C.; Mottas, I.; Nguyen, V.N.; Delie, F.; Allemann, E.; Bourquin, C. Polymer-based nanoparticles loaded with a TLR7 ligand to target the lymph node for immunostimulation. Int. J. Pharm. 2018, 535, 444–451.
  45. Vu, M.N.; Kelly, H.G.; Wheatley, A.K.; Peng, S.; Pilkington, E.H.; Veldhuis, N.A.; Davis, T.P.; Kent, S.J.; Truong, N.P. Cellular interactions of liposomes and PISA nanoparticles during human blood flow in a microvascular network. Small 2020, 16, e2002861.
  46. Henriksen-Lacey, M.; Christensen, D.; Bramwell, V.W.; Lindenstrøm, T.; Agger, E.M.; Andersen, P.; Perrie, Y. Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N′,N′-Dimethylaminoethane)carbomyl] Cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium Propane (DOTAP): Prolonged liposome retention mediates stronger Th1 responses. Mol. Pharm. 2011, 8, 153–161.
  47. Sato, Y.; Hatakeyama, H.; Sakurai, Y.; Hyodo, M.; Akita, H.; Harashima, H. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. J. Control Release 2012, 163, 267–276.
  48. Hirai, Y.; Saeki, R.; Song, F.; Koide, H.; Fukata, N.; Tomita, K.; Maeda, N.; Oku, N.; Asai, T. Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery. Int. J. Pharm. 2020, 585, 119479.
  49. Lou, G.; Anderluzzi, G.; Schmidt, S.T.; Woods, S.; Gallorini, S.; Brazzoli, M.; Giusti, F.; Ferlenghi, I.; Johnson, R.N.; Roberts, C.W.; et al. Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection. J. Control. Release 2020, 325, 370–379.
  50. Wei, T.; Cheng, Q.; Min, Y.L.; Olson, E.N.; Siegwart, D.J. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat. Commun. 2020, 11, 3232.
  51. Moghimi, S.M. The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. Biomaterials 2006, 27, 136–144.
  52. Zukancic, D.; Suys, E.J.A.; Pilkington, E.H.; Algarni, A.; Al-Wassiti, H.; Truong, N.P. the importance of poly(ethylene glycol) and lipid structure in targeted gene delivery to lymph nodes by lipid nanoparticles. Pharmaceutics 2020, 12, 68.
  53. Hoang Thi, T.T.; Pilkington, E.H.; Nguyen, D.H.; Lee, J.S.; Park, K.D.; Truong, N.P. The importance of poly(ethylene glycol) alternatives for overcoming peg immunogenicity in drug delivery and bioconjugation. Polymers 2020, 12, 298.
  54. Vu, M.N.; Kelly, H.G.; Tan, H.-X.; Juno, J.A.; Esterbauer, R.; Davis, T.P.; Truong, N.P.; Wheatley, A.K.; Kent, S.J. Hemagglutinin functionalized liposomal vaccines enhance germinal center and follicular helper T cell immunity. Adv. Healthc. Mater. 2002, 142, 2002142.
  55. Veiga, N.; Goldsmith, M.; Diesendruck, Y.; Ramishetti, S.; Rosenblum, D.; Elinav, E.; Behlke, M.A.; Benhar, I.; Peer, D. Leukocyte-specific siRNA delivery revealing IRF8 as a potential anti-inflammatory target. J. Control. Release 2019, 313, 33–41.
  56. Kedmi, R.; Veiga, N.; Ramishetti, S.; Goldsmith, M.; Rosenblum, D.; Dammes, N.; Hazan-Halevy, I.; Nahary, L.; Leviatan-Ben-Arye, S.; Harlev, M.; et al. A modular platform for targeted RNAi therapeutics. Nat. Nanotechnol. 2018, 13, 214–219.
  57. Veiga, N.; Goldsmith, M.; Granot, Y.; Rosenblum, D.; Dammes, N.; Kedmi, R.; Ramishetti, S.; Peer, D. Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes. Nat. Commun. 2018, 9, 4493.
  58. Säälik, P.; Lingasamy, P.; Toome, K.; Mastandrea, I.; Rousso-Noori, L.; Tobi, A.; Simón-Gracia, L.; Hunt, H.; Paiste, P.; Kotamraju, V.R.; et al. Peptide-guided nanoparticles for glioblastoma targeting. J. Control. Release 2019, 308, 109–118.
  59. Hunt, H.; Simón-Gracia, L.; Tobi, A.; Kotamraju, V.R.; Sharma, S.; Nigul, M.; Sugahara, K.N.; Ruoslahti, E.; Teesalu, T. Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles. J. Control. Release 2017, 260, 142–153.
  60. Kuo, Y.-C.; Shih-Huang, C.-Y.; Rajesh, R. Enhanced integrin affinity and neural differentiation of induced pluripotent stem cells using Ln5-P4-grafted amphiphilic solid lipid nanoparticles. Mater. Sci. Eng. C 2021, 118, 111339.
  61. Alvarez-Erviti, L.; Seow, Y.; Yin, H.; Betts, C.; Lakhal, S.; Wood, M.J.A. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011, 29, 341–345.
  62. Akita, H.; Kogure, K.; Moriguchi, R.; Nakamura, Y.; Higashi, T.; Nakamura, T.; Serada, S.; Fujimoto, M.; Naka, T.; Futaki, S.; et al. Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: Programmed endosomal escape and dissociation. J. Control. Release 2010, 143, 311–317.
  63. Midoux, P.; Pichon, C. Lipid-based mRNA vaccine delivery systems. Expert. Rev. Vaccines 2015, 14, 221–234.
  64. Du, Z.; Munye, M.M.; Tagalakis, A.D.; Manunta, M.D.I.; Hart, S.L. The role of the helper lipid on the DNA transfection efficiency of lipopolyplex formulations. Sci. Rep. 2014, 4, 7107.
  65. Wei, Y.; Gu, X.; Cheng, L.; Meng, F.; Storm, G.; Zhong, Z. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo. Acta Biomater. 2019, 92, 196–204.
  66. Wei, L.; Guo, X.Y.; Yang, T.; Yu, M.Z.; Chen, D.W.; Wang, J.C. Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles. Int. J. Pharm. 2016, 510, 394–405.
  67. Wu, Y.; Zhang, Y.; Zhang, W.; Sun, C.; Wu, J.; Tang, J. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles. Colloids Surf. B Biointerfaces 2016, 138, 60–69.
  68. Deken, M.M.; Kijanka, M.M.; Beltran Hernandez, I.; Slooter, M.D.; de Bruijn, H.S.; van Diest, P.J.; van Bergen En Henegouwen, P.M.P.; Lowik, C.; Robinson, D.J.; Vahrmeijer, A.L.; et al. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session. J. Control Release 2020, 323, 269–281.
  69. Wang, H.; Tam, Y.Y.C.; Chen, S.; Zaifman, J.; van der Meel, R.; Ciufolini, M.A.; Cullis, P.R. The niemann-pick C1 inhibitor NP3.47 enhances gene silencing potency of lipid nanoparticles containing siRNA. Mol. Ther. 2016, 24, 2100–2108.
  70. Agrawal, M.; Saraf, S.; Saraf, S.; Dubey, S.K.; Puri, A.; Patel, R.J.; Ajazuddin; Ravichandiran, V.; Murty, U.S.; Alexander, A. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. J. Control. Release 2020, 321, 372–415.
  71. Fan, Y.; Marioli, M.; Zhang, K. Analytical characterization of liposomes and other lipid nanoparticles for drug delivery. J. Pharm. Biomed. Anal. 2021, 192, 113642.
  72. Lamichhane, N.; Udayakumar, T.S.; D’Souza, W.D.; Simone, C.B., 2nd; Raghavan, S.R.; Polf, J.; Mahmood, J. Liposomes: Clinical applications and potential for image-guided drug delivery. Molecules 2018, 23, 288.
  73. Mebiopharm—Product & Technologies. Available online: (accessed on 21 January 2021).
  74. Bulbake, U.; Doppalapudi, S.; Kommineni, N.; Khan, W. Liposomal formulations in clinical use: An updated review. Pharmaceutics 2017, 9, 12.
  75. Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors. Available online: (accessed on 21 January 2021).
  76. TLD-1, a Novel Liposomal Doxorubicin, in Patients with Advanced Solid Tumors. Available online: (accessed on 12 March 2021).
  77. Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma. Available online: (accessed on 20 February 2021).
  78. Munster, P.; Krop, I.E.; LoRusso, P.; Ma, C.; Siegel, B.A.; Shields, A.F.; Molnár, I.; Wickham, T.J.; Reynolds, J.; Campbell, K.; et al. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: A phase 1 dose-escalation study. Br. J. Cancer 2018, 119, 1086–1093.
  79. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC). Available online: (accessed on 20 February 2021).
  80. ThermoDox®—Enhancing the Efficacy of Doxorubicin with Heat-Activated Liposome Technology. Available online: (accessed on 10 February 2021).
  81. Merrimack Stops the Phase 2 HERMIONE Trial of MM-302 in HER2-Positive Metastatic Breast Cancer Patients. Available online: (accessed on 25 January 2021).
  82. Seetharamu, N.; Kim, E.; Hochster, H.; Martin, F.; Muggia, F. Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. Anticancer Res. 2010, 30, 541–545.
  83. Kim, E.S.; Lu, C.; Khuri, F.R.; Tonda, M.; Glisson, B.S.; Liu, D.; Jung, M.; Hong, W.K.; Herbst, R.S. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 2001, 34, 427–432.
  84. White, S.C.; Lorigan, P.; Margison, G.P.; Margison, J.M.; Martin, F.; Thatcher, N.; Anderson, H.; Ranson, M. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br. J. Cancer 2006, 95, 822–828.
  85. Wu, H.; Ramanathan, R.K.; Zamboni, B.A.; Strychor, S.; Ramalingam, S.; Edwards, R.P.; Friedland, D.M.; Stoller, R.G.; Belani, C.P.; Maruca, L.J.; et al. Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. J. Clin. Pharm. 2012, 52, 180–194.
  86. Fan, Y.; Zhang, Q. Development of liposomal formulations: From concept to clinical investigations. Asian J. Pharm. Sci. 2013, 8, 81–87.
  87. Kulkarni, J.A.; Cullis, P.R.; van der Meel, R. Lipid nanoparticles enabling gene therapies: From concepts to clinical utility. Nucleic Acid Ther. 2018, 28, 146–157.
  88. Rudra, A.; Li, J.; Shakur, R.; Bhagchandani, S.; Langer, R. Trends in therapeutic conjugates: Bench to clinic. Bioconjugate Chem. 2020, 31, 462–473.
  89. Hu, B.; Zhong, L.; Weng, Y.; Peng, L.; Huang, Y.; Zhao, Y.; Liang, X.J. Therapeutic siRNA: State of the art. Signal Transduct. Target. Ther. 2020, 5, 101.
  90. Scott, L.J. Givosiran—First Approval. Drugs 2020, 80, 335–339.
  91. Mucker, E.M.; Karmali, P.P.; Vega, J.; Kwilas, S.A.; Wu, H.; Joselyn, M.; Ballantyne, J.; Sampey, D.; Mukthavaram, R.; Sullivan, E.; et al. Lipid nanoparticle formulation increases efficiency of DNA-vectored vaccines/immunoprophylaxis in animals including transchromosomic bovines. Sci. Rep. 2020, 10, 8764.
  92. Addressing Key Challenges of Lipid-Mediated Delivery Systems for mRNA through Innovation. Available online: (accessed on 28 January 2021).
  93. Ramaswamy, S.; Tonnu, N.; Tachikawa, K.; Limphong, P.; Vega, J.B.; Karmali, P.P.; Chivukula, P.; Verma, I.M. Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc. Natl. Acad. Sci. USA 2017, 114, E1941–E1950.
  94. Demeure, M.J.; Armaghany, T.; Ejadi, S.; Ramanathan, R.K.; Elfiky, A.; Strosberg, J.R.; Smith, D.C.; Whitsett, T.; Liang, W.S.; Sekar, S.; et al. A phase I/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC). J. Clin. Oncol. 2016, 34, 2547.
  95. Halfdanarson, T.R.; Armaghany, T.; Ejadi, S.; Northfelt, D.W.; Ramanathan, R.K.; Strosberg, J.; Smith, D.C.; Vaena, D.; Fredlund, P.; Semple, S.C.; et al. A phase I/II study of TKM-080301, a RNAi therapeutic directed against polo-like kinase 1(PLK1), in patients with gastrointestinal neuroendocrine tumors (GI-NET). Pancreas 2016, 45, 475–476.
  96. Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma. Available online: (accessed on 25 January 2021).
  97. El Dika, I.; Lim, H.Y.; Yong, W.P.; Lin, C.C.; Yoon, J.H.; Modiano, M.; Freilich, B.; Choi, H.J.; Chao, T.Y.; Kelley, R.K.; et al. An open-label, multicenter, phase I, dose escalation study with phase ii expansion cohort to determine the safety, pharmacokinetics, and preliminary antitumor activity of intravenous TKM-080301 in subjects with advanced hepatocellular carcinoma. Oncology 2019, 24, 747.
  98. Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients with Hepatocellular Carcinoma. Available online: (accessed on 25 January 2021).
  99. Wagner, M.J.; Mitra, R.; McArthur, M.J.; Baze, W.; Barnhart, K.; Wu, S.Y.; Rodriguez-Aguayo, C.; Zhang, X.; Coleman, R.L.; Lopez-Berestein, G.; et al. Preclinical mammalian safety studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Mol. Cancer Ther. 2017, 16, 1114–1123.
  100. EphA2 siRNA in Treating Patients with Advanced or Recurrent Solid Tumors. Available online: (accessed on 25 January 2021).
  101. Study of Safety and Tolerability of DCR HBVS. Available online: (accessed on 25 January 2021).
  102. McGoron, A.J. Perspectives on the future of nanomedicine to impact patients: An analysis of US Federal Funding and interventional clinical trials. Bioconjugate Chem. 2020, 31, 436–447.
  103. Cervantes, A.; Alsina, M.; Tabernero, J.; Infante, J.R.; LoRusso, P.; Shapiro, G.; Paz-Ares, L.G.; Falzone, R.; Hill, J.; Cehelsky, J.; et al. Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. J. Clin. Oncol. 2011, 29, 3025.
  104. Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment. Available online: (accessed on 28 January 2021).
  105. Patel, M.R.; Bauer, T.M.; Jimeno, A.; Wang, D.; LoRusso, P.; Do, K.T.; Stemmer, S.M.; Maurice-Dror, C.; Geva, R.; Zacharek, S.; et al. A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab. J. Clin. Oncol. 2020, 38, 3092.
  106. Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients with Advanced Malignancies. Available online: (accessed on 25 January 2021).
  107. Dose Escalation and Efficacy Study of mRNA 2416 for Intratumoral Injection Alone and in Combination with Durvalumab for Patients With Advanced Malignancies. Available online: (accessed on 10 January 2021).
  108. Yarosh, D.; Klein, J.; Kibitel, J.; Alas, L.; O′Connor, A.; Cummings, B.; Grob, D.; Gerstein, D.; Gilchrest, B.A.; Ichihashi, M.; et al. Enzyme therapy of xeroderma pigmentosum: Safety and efficacy testing of T4N5 liposome lotion containing a prokaryotic DNA repair enzyme. Photodermatol. Photoimmunol. Photomed. 1996, 12, 122–130.
  109. Tolcher, A.W.; Papadopoulos, K.P.; Patnaik, A.; Rasco, D.W.; Martinez, D.; Wood, D.L.; Fielman, B.; Sharma, M.; Janisch, L.A.; Brown, B.D.; et al. Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors. J. Clin. Oncol. 2015, 33, 11006.
  110. Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients with Solid Tumors, Multiple Myeloma, or Lymphoma. Available online: (accessed on 25 January 2021).
  111. Ozcan, G.; Ozpolat, B.; Coleman, R.L.; Sood, A.K.; Lopez-Berestein, G. Preclinical and clinical development of siRNA-based therapeutics. Adv. Drug Deliv. Rev. 2015, 87, 108–119.
  112. Kadelka, S.; Dahari, H.; Ciupe, S.M. Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection. Sci. Rep. 2021, 11, 200.
  113. ElBagoury, M.; Tolba, M.M.; Nasser, H.A.; Jabbar, A.; Elagouz, A.M.; Aktham, Y.; Hutchinson, A. The find of COVID-19 vaccine: Challenges and opportunities. J. Infect. Public Health 2021, 14, 389–416.
  114. Van Riel, D.; de Wit, E. Next-generation vaccine platforms for COVID-19. Nat. Mater. 2020, 19, 810–812.
  115. Koirala, A.; Joo, Y.J.; Khatami, A.; Chiu, C.; Britton, P.N. Vaccines for COVID-19: The current state of play. Paediatr. Respir. Rev. 2020, 35, 43–49.
  116. Ng, W.H.; Liu, X.; Mahalingam, S. Development of vaccines for SARS-CoV-2. F1000Research 2020, 9.
  117. Pardi, N.; Hogan, M.J.; Porter, F.W.; Weissman, D. mRNA vaccines—A new era in vaccinology. Nat. Rev. Drug Discov. 2018, 17, 261–279.
  118. Lee, K.; Kim, S.Y.; Seo, Y.; Kim, M.H.; Chang, J.; Lee, H. Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy. Biomater. Sci. 2020, 8, 1101–1105.
  119. Shi, S.; Zhu, H.; Xia, X.; Liang, Z.; Ma, X.; Sun, B. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. Vaccine 2019, 37, 3167–3178.
  120. Bonam, S.R.; Partidos, C.D.; Halmuthur, S.K.M.; Muller, S. An overview of novel adjuvants designed for improving vaccine efficacy. Trends Pharmacol. Sci. 2017, 38, 771–793.
  121. Reed, S.G.; Tomai, M.; Gale, M.J., Jr. New horizons in adjuvants for vaccine development. Curr. Opin. Immunol. 2020, 65, 97–101.
  122. Theobald, N. Emerging vaccine delivery systems for COVID-19: Functionalised silica nanoparticles offer a potentially safe and effective alternative delivery system for DNA/RNA vaccines and may be useful in the hunt for a COVID-19 vaccine. Drug Discov. Today 2020.
  123. Shin, M.D.; Shukla, S.; Chung, Y.H.; Beiss, V.; Chan, S.K.; Ortega-Rivera, O.A.; Wirth, D.M.; Chen, A.; Sack, M.; Pokorski, J.K.; et al. COVID-19 vaccine development and a potential nanomaterial path forward. Nat. Nanotechnol. 2020, 15, 646–655.
  124. O’Hagan, D.T.; Lodaya, R.N.; Lofano, G. The continued advance of vaccine adjuvants—“We can work it out”. Semin. Immunol. 2020, 50, 101426.
  125. Manabe, Y.; Chang, T.-C.; Fukase, K. Recent advances in self-adjuvanting glycoconjugate vaccines. Drug Discov. Today Technol. 2020, in press.
  126. Anderluzzi, G.; Schmidt, S.T.; Cunliffe, R.; Woods, S.; Roberts, C.W.; Veggi, D.; Ferlenghi, I.; O′Hagan, D.T.; Baudner, B.C.; Perrie, Y. Rational design of adjuvants for subunit vaccines: The format of cationic adjuvants affects the induction of antigen-specific antibody responses. J. Control Release 2020, 330, 933–944.
  127. Shih, H.I.; Wu, C.J.; Tu, Y.F.; Chi, C.Y. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. Biomed. J. 2020, 43, 341–354.
  128. Weiss, C.; Carriere, M.; Fusco, L.; Capua, I.; Regla-Nava, J.A.; Pasquali, M.; Scott, J.A.; Vitale, F.; Unal, M.A.; Mattevi, C.; et al. Toward nanotechnology-enabled approaches against the COVID-19 pandemic. ACS Nano 2020, 14, 6383–6406.
  129. Shi, Y. clinical translation of nanomedicine and biomaterials for cancer immunotherapy: Progress and perspectives. Adv. Ther. 2020, 1900215.
  130. Evaluation of the Safety and Tolerability of, i.v. Administration of a Cancer Vaccine in Patients with Advanced Melanoma. Available online: (accessed on 25 January 2021).
  131. Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination With Pembrolizumab in Subjects with Unresectable Solid Tumors (KEYNOTE-603). Available online: (accessed on 25 January 2021).
  132. An Efficacy Study of Adjuvant Treatment with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Patients with High-Risk Melanoma (KEYNOTE-942). Available online: (accessed on 25 January 2021).
  133. Tetravalent RNA-Lipoplex Cancer Vaccine (Concept Id: C4053753). Available online: (accessed on 15 February 2021).
  134. Kranz, L.M.; Diken, M.; Haas, H.; Kreiter, S.; Loquai, C.; Reuter, K.C.; Meng, M.; Fritz, D.; Vascotto, F.; Hefesha, H.; et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 2016, 534, 396–401.
  135. Stimuvax—Investigational Therapeutic Cancer Vaccine. Available online: (accessed on 2 April 2021).
  136. McKay, P.F.; Hu, K.; Blakney, A.K.; Samnuan, K.; Brown, J.C.; Penn, R.; Zhou, J.; Bouton, C.R.; Rogers, P.; Polra, K.; et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat. Commun. 2020, 11, 3523.
  137. Vaccines–COVID19 Vaccine Tracker Home Page. Available online: (accessed on 25 January 2021).
  138. Chauhan, G.; Madou, M.J.; Kalra, S.; Chopra, V.; Ghosh, D.; Martinez-Chapa, S.O. Nanotechnology for COVID-19: Therapeutics and Vaccine Research. ACS Nano 2020, 14, 7760–7782.
  139. Zhang, J.; Xie, B.; Hashimoto, K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav. Immun. 2020, 87, 59–73.
  140. (WHO) T.W.H.O. Draft Landscape of COVID-19 Candidate Vaccines. Available online: (accessed on 2 December 2020).
  141. Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19). Available online: (accessed on 25 January 2021).
  142. Moderna COVID Vaccine Becomes Second to Get US Authorization. Available online: (accessed on 25 January 2021).
  143. Pfizer-BioNTech COVID-19 Vaccine. Available online: (accessed on 25 January 2021).
  144. Sahin, U.; Muik, A.; Derhovanessian, E.; Vogler, I.; Kranz, L.M.; Vormehr, M.; Baum, A.; Pascal, K.; Quandt, J.; Maurus, D.; et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 2020, 586, 594–599.
  145. Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects. Available online: (accessed on 25 January 2021).
  146. Brown, S.; Brown, T.; Cederna, P.S.; Rohrich, R.J. The race for a COVID-19 Vaccine: Current trials, novel technologies, and future directions. Plast. Reconstr. Surg. Glob. Open 2020, 8, e3206.
  147. Ward, D.; McCormack, S. Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women (ISRCTN17072692). BioMedCentral 2020.
  148. A Phase I Clinical Trial to Evaluate the Safety, Tolerance and Preliminary Immunogenicity of Different Doses of a SARS-CoV-2 mRNA Vaccine in Population Aged 18-59 Years and 60 Years and Above. Available online: (accessed on 25 January 2021).
  149. Zhang, N.N.; Li, X.F.; Deng, Y.Q.; Zhao, H.; Huang, Y.J.; Yang, G.; Huang, W.J.; Gao, P.; Zhou, C.; Zhang, R.R.; et al. A thermostable mRNA vaccine against COVID-19. Cell 2020, 182, 1271–1283.
  150. Lu, J.; Lu, G.; Tan, S.; Xia, J.; Xiong, H.; Yu, X.; Qi, Q.; Yu, X.; Li, L.; Yu, H.; et al. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 2020, 30, 936–939.
  151. A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults. Available online: (accessed on 25 January 2021).
  152. Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals. Available online: (accessed on 25 January 2021).
  153. Kaur, S.P.; Gupta, V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020, 288, 198114.
  154. Walls, A.C.; Park, Y.J.; Tortorici, M.A.; Wall, A.; McGuire, A.T.; Veesler, D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020, 181, 281–292.
  155. Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older. Available online: (accessed on 25 January 2021).
  156. A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19. Available online: (accessed on 25 January 2021).
  157. Bonam, S.R.; Kotla, N.G.; Bohara, R.A.; Rochev, Y.; Webster, T.J.; Bayry, J. Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections. Nano Today 2021, 36, 101051.
  158. Sanofi and Translate Bio mRNA COVID-19 Vaccine Candidate Induced High Antibody Levels in Preclinical Studies. 25 January. Available online: (accessed on 25 January 2021).
  159. Sanofi, Translate Bio Start Phase 1:2 Clinical Trial Of MRNA COVID-19 Vaccine Candidate. Available online: (accessed on 12 March 2021).
  160. CanSino Biologics and Precision NanoSystems Announce Collaboration to Co-Develop a COVID-19 RNA Vaccine. Available online: (accessed on 25 January 2021).
  161. Development of IMV’s DPX-COVID-19 Vaccine Progresses Apace. Available online: (accessed on 25 January 2021).
  162. Shirai, S.; Kawai, A.; Shibuya, M.; Munakata, L.; Omata, D.; Suzuki, R.; Yoshioka, Y. Lipid nanoparticle acts as a potential adjuvant for influenza split vaccine without inducing inflammatory responses. Vaccines 2020, 8.
  163. Swaminathan, G.; Thoryk, E.A.; Cox, K.S.; Meschino, S.; Dubey, S.A.; Vora, K.A.; Celano, R.; Gindy, M.; Casimiro, D.R.; Bett, A.J. A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens. Vaccine 2016, 34, 110–119.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback